2BB score and signals
Axsome Therapeutics, Inc.’s current 2BB score is 61 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|
| Activity | 81 | Very High |
| Momentum | 57 | Stable |
| Financial strength | 32 | Weak |
| Quality | 99 | Very Strong |
| Risk | 32 | Low |
Company facts
| CEO | Herriot Tabuteau |
| Founded | 2012 |
| Employees | 1.35K |
| 52-week range | $123.42 – $260.19 |
Recent earnings
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|
| 2027-02-10 | — | 0.1359 | — | $300.65M |
| 2026-11-02 | — | -0.4573 | — | $261.66M |
| 2026-08-10 | -0.99 | -0.8616 | $218.38M | $225.65M |
| 2026-05-04 | -1.26 | -0.9139 | $191.20M | $194.03M |
Related companies
